Fetal adenocarcinoma

Last updated

Fetal adenocarcinoma
Other namesWell differentiated fetal adenocarcinoma, high-grade fetal adenocarcinoma, pulmonary adenocarcinoma of fetal type, and pulmonary endodermal tumour resembling fetal lung. [1]
Fetal adenocarcinoma of the lung -- high mag.jpg
Micrograph showing fetal adenocarcinoma. H&E stain.

Fetal adenocarcinoma (FA) of the lung is a rare subtype of pulmonary adenocarcinoma that exhibits tissue architecture and cell characteristics that resemble fetal lung tissue upon microscopic examination. It is currently considered a variant of solid adenocarcinoma with mucin production. [1]

Contents

Symptoms and signs

FA can produce repeated hemoptysis, possibly related to cavitation of the tumor. [2]

Other presenting symptoms described have included: flu-like syndrome with cough and fever, [3]

Genetics

Due to its rarity, little is known of the genetics of FA. [4]

One small series of 6 cases showed that MDM2 protein was expressed in 5 of them (83%), and p53 protein was overexpressed in 50%. [5] However, a larger series of 12 cases revealed no p53 gene mutations. [4]

Histogenesis

The details of the histogenesis of FA remain unknown and highly debated. [6] Adenocarcinomas are most often highly heterogeneous peripheral tumors, [7] and are thought to arise from malignant transformation of primitive cells that can exhibit differentiation characteristics of Club cells, Type II pneumocytes, bronchiolar surface cells, bronchial gland cells, or goblet cells. [8] [9]

Most FA's are well or moderately differentiated tumors, although high-grade, poorly differentiated variants have been described. [1] [10] [11] Tissue resembling FA can also be found admixed with a component made up of primitive blastoma-like cells. In such cases, these biphasic tumors are classified as a form of pulmonary blastoma because the presence of the blastomatous cells dramatically worsens the prognosis. [11] [12]

FA can occur in combination with other forms of lung cancer, particularly other variants of adenocarcinoma. [1] There also seems to be an association with clear cell lung cancer variants. [13] A case of combined small cell lung carcinoma featuring components of FA and cells resembling those from carcinoid tumor has been reported, illustrating the unique complexity and heterogeneity of divergent histogenesis and cell differentiation in lung cancer. [14]

Diagnosis

FA is an epithelial tumor whose cells and architecture resemble that of fetal lung tissues in the pseudoglandular stage of development (which occurs at about 10–16 weeks gestation in the human), [6] with complex glandular structures and morules with cell nuclei that appear clear due to the accumulation of biotin. [15]

While FA can be diagnosed via biopsy, bronchial brushings, and immunocytochemistry, [16] examination of the whole tumor is required to rule out biphasic pulmonary blastoma, a mixed tumor of higher aggressiveness, wherein FA occurs admixed with primitive blastoma cells. [6]

Although it is not normally considered a fast-growing malignant neoplasm, FA can exhibit high uptake on FDG-PET scanning. [17]

Identification of aberrant nuclear localization of a mutated protein product of the beta-catenin gene has been proposed as a diagnostic tool for FA. [18]

Although FA's usually occur as nodules or masses, they can sometimes present as a multifocal disease. [19]

Treatment

Because of its extreme rarity, there have been no controlled clinical trials of treatment regimens for FA and, as a result, there are no evidence-based treatment guidelines. [6] Complete surgical resection is the treatment of choice in FA, as it is in nearly all forms of lung cancer. [20]

Anecdotal reports suggest that FA is rarely highly sensitive to cytotoxic drugs [20] or radiation. [2] Case reports suggest that chemotherapy with UFT may be useful in FA. [13]

Prognosis

The prognosis of patients with FA as a whole is considered to be better than that of most other forms of non-small cell carcinoma, including biphasic pulmonary blastoma. [21] [22]

Incidence

FA is a rare tumor, with a relative incidence estimated to be no more than 0.5% of all lung cancers. [2] [23] [24] [6]

FA is exceptionally rare in children, with only a handful of cases reported to date, [25] However, several case reports have involved FA's in pregnant women or the early postnatal period. [2] [24]

Related Research Articles

<span class="mw-page-title-main">Adenocarcinoma</span> Medical condition

Adenocarcinoma is a type of cancerous tumor that can occur in several parts of the body. It is defined as neoplasia of epithelial tissue that has glandular origin, glandular characteristics, or both. Adenocarcinomas are part of the larger grouping of carcinomas, but are also sometimes called by more precise terms omitting the word, where these exist. Thus invasive ductal carcinoma, the most common form of breast cancer, is adenocarcinoma but does not use the term in its name—however, esophageal adenocarcinoma does to distinguish it from the other common type of esophageal cancer, esophageal squamous cell carcinoma. Several of the most common forms of cancer are adenocarcinomas, and the various sorts of adenocarcinoma vary greatly in all their aspects, so that few useful generalizations can be made about them.

Pleuropulmonary blastoma (PPB) is a rare cancer originating in the lung or pleural cavity. It occurs most often in infants and young children but also has been reported in adults. In a retrospective review of 204 children with lung tumors, pleuropulmonary blastoma and carcinoid tumor were the most common primary tumors. Pleuropulmonary blastoma is regarded as malignant. The male:female ratio is approximately one.

<span class="mw-page-title-main">Blastoma</span> Type of cancer arising from precursor cells

A blastoma is a type of cancer, more common in children, that is caused by malignancies in precursor cells, often called blasts. Examples are nephroblastoma, medulloblastoma, and retinoblastoma. The suffix -blastoma is used to imply a tumor of primitive, incompletely differentiated cells, e.g., chondroblastoma is composed of cells resembling the precursor of chondrocytes.

<span class="mw-page-title-main">Adenocarcinoma in situ of the lung</span> Medical condition

Adenocarcinoma in situ (AIS) of the lung —previously included in the category of "bronchioloalveolar carcinoma" (BAC)—is a subtype of lung adenocarcinoma. It tends to arise in the distal bronchioles or alveoli and is defined by a non-invasive growth pattern. This small solitary tumor exhibits pure alveolar distribution and lacks any invasion of the surrounding normal lung. If completely removed by surgery, the prognosis is excellent with up to 100% 5-year survival.

<span class="mw-page-title-main">TP63</span> Protein-coding gene in the species Homo sapiens

Tumor protein p63, typically referred to as p63, also known as transformation-related protein 63 is a protein that in humans is encoded by the TP63 gene.

<span class="mw-page-title-main">Signet ring cell carcinoma</span> Medical condition

Signet ring cell carcinoma (SRCC) is a rare form of highly malignant adenocarcinoma that produces mucin. It is an epithelial malignancy characterized by the histologic appearance of signet ring cells.

<span class="mw-page-title-main">NK2 homeobox 1</span> Mammalian protein found in Homo sapiens

NK2 homeobox 1 (NKX2-1), also known as thyroid transcription factor 1 (TTF-1), is a protein which in humans is encoded by the NKX2-1 gene.

<span class="mw-page-title-main">Combined small-cell lung carcinoma</span> Medical condition

Combined small cell lung carcinoma is a form of multiphasic lung cancer that is diagnosed by a pathologist when a malignant tumor, arising from transformed cells originating in lung tissue, contains a component of;small cell lung carcinoma (SCLC), admixed with one components of any histological variant of non-small cell lung carcinoma (NSCLC) in any relative proportion.

Large cell lung carcinoma with rhabdoid phenotype (LCLC-RP) is a rare histological form of lung cancer, currently classified as a variant of large cell lung carcinoma (LCLC). In order for a LCLC to be subclassified as the rhabdoid phenotype variant, at least 10% of the malignant tumor cells must contain distinctive structures composed of tangled intermediate filaments that displace the cell nucleus outward toward the cell membrane. The whorled eosinophilic inclusions in LCLC-RP cells give it a microscopic resemblance to malignant cells found in rhabdomyosarcoma (RMS), a rare neoplasm arising from transformed skeletal muscle. Despite their microscopic similarities, LCLC-RP is not associated with rhabdomyosarcoma.

Epithelial-myoepithelial carcinoma of the lung is a very rare histologic form of malignant epithelial neoplasm ("carcinoma") arising from lung tissue.

Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.

Mucinous cystadenocarcinoma of the lung (MCACL) is a very rare malignant mucus-producing neoplasm arising from the uncontrolled growth of transformed epithelial cells originating in lung tissue.

<span class="mw-page-title-main">Sarcomatoid carcinoma</span> Medical condition

Sarcomatoid carcinoma, sometimes referred to as pleomorphic carcinoma, is a relatively uncommon form of cancer whose malignant cells have histological, cytological, or molecular properties of both epithelial tumors ("carcinoma") and mesenchymal tumors ("sarcoma"). It is believed that sarcomatoid carcinomas develop from more common forms of epithelial tumors.

Acinar adenocarcinoma is a histological subtype of gland-forming cancer that is diagnosed when cuboidal and/or columnar shaped malignant cells in the neoplastic tissue form acini and tubules. It is a common form of cancer occurring in the lung and prostate gland.

Sarcomatoid carcinoma of the lung is a term that encompasses five distinct histological subtypes of lung cancer, including (1) pleomorphic carcinoma, (2) spindle cell carcinoma, (3) giant cell carcinoma, (4) carcinosarcoma, or (5) pulmonary blastoma.

<span class="mw-page-title-main">Giant-cell carcinoma of the lung</span> Medical condition

Giant-cell carcinoma of the lung (GCCL) is a rare histological form of large-cell lung carcinoma, a subtype of undifferentiated lung cancer, traditionally classified within the non-small-cell lung carcinomas (NSCLC).

Adenosquamous lung carcinoma (AdSqLC) is a biphasic malignant tumor arising from lung tissue that is composed of at least 10% by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells.

Salivary gland–like carcinomas of the lung generally refers a class of rare cancers that arise from the uncontrolled cell division (mitosis) of mutated cancer stem cells in lung tissue. They take their name partly from the appearance of their abnormal cells, whose structure and features closely resemble those of cancers that form in the major salivary glands of the head and neck. Carcinoma is a term for malignant neoplasms derived from cells of epithelial lineage, and/or that exhibit cytological or tissue architectural features characteristically found in epithelial cells.

Basaloid squamous cell carcinoma (Bas-SqCC) is an uncommon histological variant of lung cancer composed of cells exhibiting cytological and tissue architectural features of both squamous cell lung carcinoma and basal cell carcinoma.

Basaloid large cell carcinoma of the lung, is a rare histological variant of lung cancer featuring certain distinctive cytological, tissue architectural, and immunohistochemical characteristics and clinical behavior.

References

  1. 1 2 3 4 Travis, William D; Brambilla, Elisabeth; Muller-Hermelink, H Konrad; et al., eds. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN   92-832-2418-3. Archived from the original (PDF) on 23 August 2009. Retrieved 14 April 2012.
  2. 1 2 3 4 Thompson RJ, Hasleton PS, Taylor PM, Woodhead M, Byrd LM (2010). "Haemoptysis in pregnancy caused by a well-differentiated fetal adenocarcinoma: a case report". J Med Case Rep. 4: 17. doi: 10.1186/1752-1947-4-17 . PMC   2823759 . PMID   20205788.
  3. ↑ Longo M, Levra MG, Capelletto E, et al. (April 2008). "Fetal adenocarcinoma of the lung in a 25-year-old woman". J Thorac Oncol. 3 (4): 441–3. doi:10.1097/JTO.0b013e318169cd9a. hdl: 2318/27869 . PMID   18379367.
  4. 1 2 Bodner SM, Koss MN (November 1996). "Mutations in the p53 gene in pulmonary blastomas: immunohistochemical and molecular studies". Hum. Pathol. 27 (11): 1117–23. doi:10.1016/S0046-8177(96)90302-0. PMID   8912818.
  5. ↑ Pacinda SJ, Ledet SC, Gondo MM, et al. (June 1996). "p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas". Hum. Pathol. 27 (6): 542–6. doi:10.1016/S0046-8177(96)90159-8. PMID   8666362.
  6. 1 2 3 4 5 Cutler CS, Michel RP, Yassa M, Langleben A (February 1998). "Pulmonary blastoma: case report of a patient with a 7-year remission and review of chemotherapy experience in the world literature". Cancer. 82 (3): 462–7. doi: 10.1002/(sici)1097-0142(19980201)82:3<462::aid-cncr6>3.0.co;2-r . PMID   9452262.
  7. ↑ Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R (June 1985). "Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases". Hum. Pathol. 16 (6): 569–79. doi:10.1016/S0046-8177(85)80106-4. PMID   2987102.
  8. ↑ Shimosato Y, Kodama T, Kameya T (1982). "Morphogenesis of peripheral type adenocarcinoma of the lung". In Shimosato Y, Melamed MR, Nettesheim P (eds.). Morphogenesis of lung cancer. Boca Raton FL: CRC Press. pp. 65–89.
  9. ↑ Gupta K, Joshi K, Jindal SK, Rayat CS (2008). "Spectrum of pulmonary adenocarcinoma with ultrastructural correlation: an autopsy study from northern India". Indian J Pathol Microbiol. 51 (3): 329–36. doi: 10.4103/0377-4929.42505 . PMID   18723952.
  10. ↑ Kadota K, Haba R, Katsuki N, et al. (October 2010). "Bronchial brushing cytology of a pulmonary fetal adenocarcinoma with a poorly differentiated component". Cytopathology. 21 (5): 349–51. doi:10.1111/j.1365-2303.2009.00724.x. PMID   20015256. S2CID   12538039.
  11. 1 2 Nakatani Y, Kitamura H, Inayama Y, et al. (April 1998). "Pulmonary adenocarcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms". Am. J. Surg. Pathol. 22 (4): 399–411. doi:10.1097/00000478-199804000-00003. PMID   9537466.
  12. ↑ Adluri RK, Boddu SR, Martin-Ucar A, Duffy JP, Beggs FD, Morgan WE (February 2006). "Pulmonary blastoma—a rare tumor with variable presentation". Eur J Cardiothorac Surg. 29 (2): 236–9. doi: 10.1016/j.ejcts.2005.11.035 . PMID   16387506.
  13. 1 2 Matsuoka T, Sugi K, Matsuda E, et al. (August 2006). "[Clear cell adenocarcinoma with acomponent of well-differentiated fetal adenocareinoma; report of a case]". Kyobu Geka (in Japanese). 59 (9): 867–70. PMID   16922450.
  14. ↑ Mardini G, Pai U, Chavez AM, Tomashefski JF (March 1994). "Endobronchial adenocarcinoma with endometrioid features and prominent neuroendocrine differentiation. A variant of fetal adenocarcinoma". Cancer. 73 (5): 1383–9. doi: 10.1002/1097-0142(19940301)73:5<1383::aid-cncr2820730512>3.0.co;2-v . PMID   8111705.
  15. ↑ Nakatani Y, Masudo K, Miyagi Y, et al. (June 2002). "Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules". Mod. Pathol. 15 (6): 617–24. doi: 10.1038/modpathol.3880575 . PMID   12065775.
  16. ↑ Odashiro DN, Nguyen GK (April 2006). "Pulmonary well-differentiated fetal adenocarcinoma diagnosed by bronchial brush and immunocytochemistry". Diagn. Cytopathol. 34 (4): 308–10. doi:10.1002/dc.20409. PMID   16544342. S2CID   23802442.
  17. ↑ Paull DE, Moezzi J, Katz N, Little AG, Adebonojo SA (April 2006). "Positron emission tomography in well differentiated fetal adenocarcinoma of the lung". Clin Nucl Med. 31 (4): 213–4. doi:10.1097/01.rlu.0000204131.93846.39. PMID   16550018.
  18. ↑ Proctor L, Folpe AL, Esper A, Wolfenden LL, Force S, Logani S (January 2007). "Well-differentiated fetal adenocarcinoma of the lung: cytomorphologic features on fine-needle aspiration with emphasis on use of beta-catenin as a useful diagnostic marker". Diagn. Cytopathol. 35 (1): 39–42. doi:10.1002/dc.20583. PMID   17173289. S2CID   21460613.
  19. ↑ Furuya K, Yasumori K, Takeo S, et al. (2008). "Well-differentiated fetal adenocarcinoma of the lung: early-phase sequential high-resolution computed tomographic findings". J Comput Assist Tomogr. 32 (5): 806–9. doi:10.1097/RCT.0b013e3181573e98. PMID   18830116. S2CID   20514520.
  20. 1 2 Fujino S, Asada Y, Konishi T, Asakura S, Kato H, Mori A (December 1995). "Well-differentiated fetal adenocarcinoma of lung". Lung Cancer. 13 (3): 311–6. doi:10.1016/0169-5002(95)00489-0. PMID   8719071.
  21. ↑ Sato S, Koike T, Yamato Y, Yoshiya K, Honma K, Tsukada H (December 2006). "Resected well-differentiated fetal pulmonary adenocarcinoma and summary of 25 cases reported in Japan". Jpn. J. Thorac. Cardiovasc. Surg. 54 (12): 539–42. doi:10.1007/s11748-006-0048-8. PMID   17236658.
  22. ↑ Rossi G, Marchioni A, Sartori G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and staging: The emerging role of an old and underrated factor". Curr Respir Med Rev. 3: 69–77. doi:10.2174/157339807779941820.
  23. ↑ Luo DL, Liu YH, Zhuang HG, et al. (November 2008). "[Clinicopathologic study of pulmonary adenocarcinoma with features of bronchioloalveolar carcinoma]". Zhonghua Bing Li Xue Za Zhi (in Chinese). 37 (11): 737–42. PMID   19094707.
  24. 1 2 Esper A, Force S, Gal A, Wolfenden LL (November 2006). "A 36-year-old woman with hemoptysis and a lung mass 3 months after delivery". Chest. 130 (5): 1620–3. doi:10.1378/chest.130.5.1620. PMID   17099047.
  25. ↑ DiFurio MJ, Auerbach A, Kaplan KJ (2003). "Well-differentiated fetal adenocarcinoma: rare tumor in the pediatric population". Pediatr. Dev. Pathol. 6 (6): 564–7. doi:10.1007/s10024-003-4046-x. PMID   15018457. S2CID   32678928.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.